Type B adverse drug reactions to antibiotics and antibiotic allergy in infants and children.
adverse drug reaction
antibiotic
child
drug allergy
mislabeling
Journal
Pediatrics international : official journal of the Japan Pediatric Society
ISSN: 1442-200X
Titre abrégé: Pediatr Int
Pays: Australia
ID NLM: 100886002
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
23
12
2021
received:
25
08
2021
accepted:
11
01
2022
pubmed:
27
5
2022
medline:
28
5
2022
entrez:
26
5
2022
Statut:
ppublish
Résumé
Distinguishing allergic reactions from non-allergic type B adverse drug reactions (ADRs) to antibiotics is challenging, particularly in children, because we lack epidemiological information that can be used in primary care situations. This study aimed to investigate the characteristics of type B ADRs to antibiotics and antibiotic allergy (AA) in previously healthy children. This was a retrospective cohort study of previously healthy children admitted for treating urinary tract infections over a 10 year period. The primary outcome was the frequency of type B ADRs and AAs that were assessed by pediatricians. Secondary outcomes include demographic data about patients' backgrounds, infections, treatments, ADRs, and action against ADRs. All the data were collected via patients' medical records. Out of 791 participants, type B ADRs were reported in 77 children (9.7%), and AA labeling was performed in six children (0.8%). Physicians assessed 30.4% of type B ADRs as severe or life-threatening symptoms. All patients were discharged without long-term complications. Physicians detected the primary cause (individual patient host factors or environmental risks) in 39 cases of type B ADRs. Type B ADRs to antibiotics were frequently reported even in previously healthy children. Physicians should use appropriate techniques (e.g., specialist consulting and skin testing) when they suspect that a type B ADR might be an AA. Labeling and de-labeling programs and tools for type B ADRs related to antibiotics should be implemented to prevent the mislabeling of AA.
Sections du résumé
BACKGROUND
BACKGROUND
Distinguishing allergic reactions from non-allergic type B adverse drug reactions (ADRs) to antibiotics is challenging, particularly in children, because we lack epidemiological information that can be used in primary care situations. This study aimed to investigate the characteristics of type B ADRs to antibiotics and antibiotic allergy (AA) in previously healthy children.
METHODS
METHODS
This was a retrospective cohort study of previously healthy children admitted for treating urinary tract infections over a 10 year period. The primary outcome was the frequency of type B ADRs and AAs that were assessed by pediatricians. Secondary outcomes include demographic data about patients' backgrounds, infections, treatments, ADRs, and action against ADRs. All the data were collected via patients' medical records.
RESULTS
RESULTS
Out of 791 participants, type B ADRs were reported in 77 children (9.7%), and AA labeling was performed in six children (0.8%). Physicians assessed 30.4% of type B ADRs as severe or life-threatening symptoms. All patients were discharged without long-term complications. Physicians detected the primary cause (individual patient host factors or environmental risks) in 39 cases of type B ADRs.
CONCLUSION
CONCLUSIONS
Type B ADRs to antibiotics were frequently reported even in previously healthy children. Physicians should use appropriate techniques (e.g., specialist consulting and skin testing) when they suspect that a type B ADR might be an AA. Labeling and de-labeling programs and tools for type B ADRs related to antibiotics should be implemented to prevent the mislabeling of AA.
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15126Subventions
Organisme : Grant of National Center for Child Health and Development
ID : 2019E-1
Informations de copyright
© 2022 Japan Pediatric Society.
Références
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9.
Philip EJ, Charles PC, Karen EK et al. ASHP guidelines on adverse drug reaction monitoring and reporting. American Society of Hospital Pharmacy. Am. J. Health-Syst. Pharm. 1995; 52: 417-9.
Abrams E, Netchiporouk E, Miedzybrodzki B, Ben-Shoshan M. Antibiotic allergy in children: more than just a label. Int. Arch. Allergy Immunol. 2019; 180: 103-12.
Vyles D, Chiu A, Simpson P, Nimmer M, Adams J, Brousseau DC. Parent-reported penicillin allergy symptoms in the pediatric emergency department. Acad. Pediatr. 2017; 17: 251-5.
Zambonino MA, Corzo JL, Muñoz C et al. Diagnostic evaluation of hypersensitivity reactions to beta-lactam antibiotics in a large population of children. Pediatr. Allergy Immunol. 2014; 25: 80-7.
Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. Lancet Lond. Engl. 2019; 393: 183-98.
Turner NA, Moehring R, Sarubbi C et al. Influence of reported penicillin allergy on mortality in MSSA bacteremia. Open Forum Infect. Dis. 2018; 5: ofy042.
Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin “allergy” in hospitalized patients: a cohort study. J. Allergy Clin. Immunol. 2014; 133: 790-6.
Gerace KS, Phillips E. Penicillin allergy label persists despite negative testing. J. Allergy Clin. Immunol. Pract. 2015; 3: 815-6.
Norton AE, Konvinse K, Phillips EJ, Broyles AD. Antibiotic allergy in pediatrics. Pediatrics 2018; 141: e20172497.
Gomes ER, Brockow K, Kuyucu S et al. Drug hypersensitivity in children: report from the pediatric task force of the EAACI drug allergy interest group. Allergy 2016; 71: 149-61.
Demoly P, Adkinson NF, Brockow K et al. International consensus on drug allergy. Allergy 2014; 69: 420-37.
Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann. Allergy. Asthma Immunol. 2010; 105: 259-73.
Kurian J, Mathew J, Sowjanya K et al. Adverse drug reactions in hospitalized pediatric patients: a prospective observational study. Indian J. Pediatr. 2016; 83: 414-9.
Leopoldino RD, Santos MT, Costa TX, Martins RR, Oliveira AG. Drug related problems in the neonatal intensive care unit: incidence, characterization and clinical relevance. BMC Pediatr. 2019; 19: 134.
Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br. J. Clin. Pharmacol. 2001; 52: 77-83.
Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981; 30: 239-45.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am. J. Hosp. Pharm. 1992; 49: 2229-32.
Ibia EO, Schwartz RH, Wiedermann BL. Antibiotic rashes in children: a survey in a private practice setting. Arch. Dermatol. 2000; 136: 849-54.
Dittrich ATM, Draaisma JMT, van Puijenbroek EP, Loo DMWMT. Analysis of reporting adverse drug reactions in paediatric patients in a University hospital in the Netherlands. Paediatr. Drugs 2020; 22: 425-32.
de Las SR, Díaz-Agudelo D, Burgos-Flórez FJ, Vaca C, Serrano-Meriño DV. Adverse drug reactions in hospitalized Colombian children. Colomb. Medica. 2016; 47: 142-7.
Gill AM, Leach HJ, Hughes J, Barker C, Nunn AJ, Choonara I. Adverse drug reactions in a paediatric intensive care unit. Acta. Paediatr. 1995; 84: 438-41.
Rashed AN, Wong ICK, Cranswick N et al. Adverse drug reactions in children-international surveillance and evaluation (ADVISE): a multicentre cohort study. Drug Saf. 2012; 35: 481-94.
Caubet J-C, Kaiser L, Lemaître B, Fellay B, Gervaix A, Eigenmann PA. The role of penicillin in benign skin rashes in childhood: a prospective study based on drug rechallenge. J. Allergy Clin. Immunol. 2011; 127: 218-22.
Anci E, Braun C, Marinosci A et al. Viral infections and cutaneous drug-related eruptions. Front. Pharmacol. 2020; 11: 586407.
Horen B, Montastruc J-L, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br. J. Clin. Pharmacol. 2002; 54: 665-70.
Fajreldines A, Schnitzler E, Torres S, Panattieri N, Pellizzari M. Measurement of the incidence of care-associated adverse events at the department of pediatrics of a teaching hospital. Arch. Argent. Pediatr. 2019; 117: e106-9.
WHO [homepage on the internet]. Geneva: who.int/publications; [Cited 24 August 2021.] Available from https://www.who.int/publications/m/item/WHO-causality-assessment